Odactra™ House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) – Expanded indication
January 20, 2023 - The FDA approved ALK-Abello’s Odactra House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus), as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or by positive skin testing to licensed house dust mite allergen extracts. Odactra is approved for use in persons 12 through 65 years of age.
Top